Avigan: Fujifilm starts phase 3 clinical trial

2 Apr 2020

Avigan: Fujifilm starts phase 3 clinical trial

We are proud that FUJIFILM can make a contribution to the fight against the corona virus.

FUJIFILM is in the third phase of clinical trials with the drug Avigan. These tests are designed to verify how safe and effective the antiviral drug, also known as favipiravir, really is. The clinical trials are being conducted in Japan on Covid-19 patients.

Since March 11, it has been clear that the coronavirus outbreak is a pandemic. Since the number of patients is constantly increasing, the development of a drug to treat COVID-19 is imperative.

Avigan is a very promising drug. It is already approved in Japan as an antiviral influenza drug for production and sale. This drug has a mechanism for selective inhibition of RNA polymerase, which is involved in the replication of the influenza virus. Because of this property, it is expected that it may also have an antiviral effect on the new coronavirus. Indeed, it is classified in the same type of single-stranded RNA virus as influenza. Clinical studies are necessary to confirm this.


Fujifilm already increased production of the drug in early March and now plans to further increase production through cooperation with Japanese and global partners. This will enable the company to meet the needs of the Japanese and other governments.

As Fujifilm (Switzerland) AG, we will be happy to answer any questions you may have and help you communicate with Fujifilm Corporation.

Contact us!


glqxz9283 sfy39587stf02 mnesdcuix8